BR112012015951A2 - 4 azido-nucleosídeos como compostos anti-hcv - Google Patents

4 azido-nucleosídeos como compostos anti-hcv

Info

Publication number
BR112012015951A2
BR112012015951A2 BR112012015951A BR112012015951A BR112012015951A2 BR 112012015951 A2 BR112012015951 A2 BR 112012015951A2 BR 112012015951 A BR112012015951 A BR 112012015951A BR 112012015951 A BR112012015951 A BR 112012015951A BR 112012015951 A2 BR112012015951 A2 BR 112012015951A2
Authority
BR
Brazil
Prior art keywords
hcv
compounds
hcv compounds
nucleosides
azido
Prior art date
Application number
BR112012015951A
Other languages
English (en)
Inventor
Bernard Smith David
man Han
Sarma Keshab
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012015951A2 publication Critical patent/BR112012015951A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

-azido-nucleosídeos como compostos anti-hcv compostos da fórmula l em que r^ 1^, r^ 2^ e r^ 3^ são como aqui definidos neste documento são inibidores da polimerase ns5b do vírus da hepatite c. também são divulgadas composições e métodos para tratar a infecção pelo hcv e para inibição da replicação de hcv.
BR112012015951A 2010-01-28 2011-01-25 4 azido-nucleosídeos como compostos anti-hcv BR112012015951A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29922910P 2010-01-28 2010-01-28
PCT/EP2011/050971 WO2011092158A1 (en) 2010-01-28 2011-01-25 4 ' - azido - nucleosides as anti - hcv compunds

Publications (1)

Publication Number Publication Date
BR112012015951A2 true BR112012015951A2 (pt) 2018-10-16

Family

ID=43587111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015951A BR112012015951A2 (pt) 2010-01-28 2011-01-25 4 azido-nucleosídeos como compostos anti-hcv

Country Status (16)

Country Link
US (1) US8236779B2 (pt)
EP (1) EP2528930B1 (pt)
JP (1) JP5675849B2 (pt)
KR (1) KR101384389B1 (pt)
CN (1) CN102725303B (pt)
BR (1) BR112012015951A2 (pt)
CA (1) CA2784330C (pt)
DK (1) DK2528930T3 (pt)
ES (1) ES2437933T3 (pt)
HK (1) HK1176938A1 (pt)
MX (1) MX337050B (pt)
PL (1) PL2528930T3 (pt)
PT (1) PT2528930E (pt)
RU (1) RU2556991C2 (pt)
TW (1) TW201141488A (pt)
WO (1) WO2011092158A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040124A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852603B1 (en) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015189386A1 (en) * 2014-06-13 2015-12-17 Teva Pharmaceuticals International Gmbh Composition with a high drug load of sofosbuvir
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
WO2016204531A1 (ko) * 2015-06-16 2016-12-22 엘지전자(주) 블록 경계에 따라 적응적으로 필터링을 수행하는 방법 및 장치
JP6804790B1 (ja) * 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
CN113880903B (zh) * 2021-09-23 2024-07-02 厦门蔚嘉制药有限公司 莫那比拉韦的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100457118C (zh) * 2000-04-13 2009-02-04 法玛塞特有限公司 用于治疗肝炎病毒感染的3′-或2′-羟甲基取代的核苷衍生物
CN1646141B (zh) * 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
EP1355916B1 (en) * 2001-01-22 2007-01-10 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
NZ536123A (en) * 2002-05-06 2006-09-29 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
CN100351264C (zh) * 2002-11-19 2007-11-28 霍夫曼-拉罗奇有限公司 抗病毒核苷衍生物
TWI332507B (en) * 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
PL1962808T3 (pl) * 2005-12-14 2011-03-31 Hoffmann La Roche Preparat proleku przeciw HCV
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AR069740A1 (es) * 2007-11-29 2010-02-17 Metabasis Therapeutics Inc Compuestos nucleosidos antivirales

Also Published As

Publication number Publication date
CA2784330C (en) 2018-02-13
MX2012008443A (es) 2012-08-15
PT2528930E (pt) 2013-11-26
KR20120110177A (ko) 2012-10-09
TW201141488A (en) 2011-12-01
MX337050B (es) 2016-02-10
RU2556991C2 (ru) 2015-07-20
PL2528930T3 (pl) 2014-03-31
CN102725303B (zh) 2015-05-27
ES2437933T3 (es) 2014-01-15
RU2012136379A (ru) 2014-03-10
KR101384389B1 (ko) 2014-04-10
US20110150829A1 (en) 2011-06-23
CA2784330A1 (en) 2011-08-04
EP2528930A1 (en) 2012-12-05
WO2011092158A1 (en) 2011-08-04
EP2528930B1 (en) 2013-10-30
JP5675849B2 (ja) 2015-02-25
HK1176938A1 (en) 2013-08-09
DK2528930T3 (da) 2013-11-11
JP2013518076A (ja) 2013-05-20
US8236779B2 (en) 2012-08-07
CN102725303A (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
BR112012015951A2 (pt) 4 azido-nucleosídeos como compostos anti-hcv
MX2012003170A (es) Compuestos heterociclicos antivirales.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
CR10136A (es) Nucleósidos antivirales
TW200720285A (en) Nucleoside compounds for treating viral infections
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
EA201791776A1 (ru) Замещенные циклофаны для использования при лечении инфекции вгс
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
CR20110605A (es) Compuestos heterocíclicos antivirales
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
BR112012014299A2 (pt) composto de antivírus heterocíclicos
MX2011012541A (es) Compuestos heterociclicos antivirales.
EA201391717A1 (ru) Ингибиторы вируса гепатита с
BRPI1016167A2 (pt) compostos heterocíclicos antivirais.
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
BRPI0716060A2 (pt) inibidores de polimerase viral.
MX2011012240A (es) Compuestos heterociclicos antivirales.
MX2013004464A (es) Inhibidores de polimerasa viral.
BR112013000245A2 (pt) compostos antivirais heterocíclicos
BR112012012085A2 (pt) compostos antivirais heterocíclicos
MX2012002958A (es) Compuestos antivirales heterociclicos.
ATE531373T1 (de) Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: RIBOSCIENCE LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2551 DE 26-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]